Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma, Hepatocellular × tremelimumab × Clear all

Phase

Status

Recruiting 20 Active not recruiting 6 Not yet recruiting 2 Completed 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 3 Colorectal Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Pancreatic Neoplasms 1 Melanoma 1 Liver Neoplasms 1 Carcinoma, Hepatocellular 1 Adenocarcinoma Of Esophagus 1

Interventions

Sorafenib 11 lenvatinib 7 Radiosurgery 7 spartalizumab 6 Oxaliplatin 6 Fluorouracil 5 Radiotherapy 4 Leucovorin 3 Gemcitabine 3 Folfox protocol 3 Doxorubicin 3 fludarabine 2 cabozantinib 2 Nivolumab 2 Mitomycin 2 Electroporation 2 Cyclophosphamide 2 Cisplatin 2 Chemoembolization, Therapeutic 2 Bevacizumab 2 tremelimumab 1 toripalimab 1 tocilizumab 1 temsirolimus 1 tazemetostat 1 pirarubicin 1 perflutren 1 pembrolizumab 1 maltodextrin 1 liposomal doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06994299 2025-11-18

PRISM

Weill Medical College of Cornell University

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡